Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Blankenstein, Thomas Prof. Dr. (11) Bunse, Mario Dr. (1) Hinz, Michael Dr. (2) Kammertöns, Thomas Dr. (1) Lusatis, Simone (1) Mathas, Stephan Dr. (12) Pezzutto, Antonio Prof. Dr. (1) Scheidereit, Claus Prof. Dr. (3) Uckert, Wolfgang Prof. Dr. (3) Willimsky, Gerald Dr. (2) Wollert-Wulf, Brigitte (2) (-) Daniel, Peter Prof. Dr. (2) (-) Janz, Martin Dr. (7) (-) Leisegang, Matthias Prof. Dr. rer. nat. (1) 1999 (1) 2000 (1) (-) 2002 (2) 2003 (3) 2004 (2) 2005 (3) (-) 2006 (5) (-) 2007 (2) 2008 (2) 2009 (3) 2010 (2) 2011 (6) 2012 (2) 2013 (2) 2014 (1) 2015 (5) 2016 (2) 2017 (4) 2018 (2) 2019 (3) 2020 (5) 2021 (4) 2022 (7) 2023 (6) 2024 (1) (-) Biology of Malignant Lymphomas (7) Genetics and Genomics of Cardiovascular Diseases (1) (-) Molecular Immunology and Gene Therapy (2) Proteome Dynamics (6) Translational Oncology of Solid Tumors (1) 9 Results: Active Filter: Daniel, Peter Prof. Dr.Janz, Martin Dr.Leisegang, Matthias Prof. Dr. rer. nat.Biology of Malignant LymphomasMolecular Immunology and Gene Therapy200220062007 Sort: Result score Newest to oldest Oldest to newest January 01, 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer November 01, 2002 / Gene Ther Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes C. Scholz L. Staerck G. Willimsky T. Blankenstein B. Doerken P.T. Daniel May 15, 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas November 01, 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert April 01, 2007 / Leukemia Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells M. Janz T. Stuehmer L.T. Vassilev R.C. Bargou May 01, 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas March 15, 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou April 01, 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel February 01, 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
January 01, 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer
November 01, 2002 / Gene Ther Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes C. Scholz L. Staerck G. Willimsky T. Blankenstein B. Doerken P.T. Daniel
May 15, 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
November 01, 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
April 01, 2007 / Leukemia Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells M. Janz T. Stuehmer L.T. Vassilev R.C. Bargou
May 01, 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas
March 15, 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
April 01, 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
February 01, 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken